5-Amino-1-methylquinolinium (5-Amino-1MQ) is a cell-permeable small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide (NAM) to produce 1-methylnicotinamide (MeNAM) using S-adenosylmethionine (SAM) as the methyl donor. By inhibiting NNMT, 5-Amino-1MQ increases availability of NAM for NAD+ biosynthesis via the salvage pathway, and simultaneously preserves SAM for other methylation reactions.
NNMT is a cytosolic enzyme expressed primarily in adipose tissue, liver, and kidney. It plays a central role in one-carbon metabolism by transferring a methyl group from SAM to nicotinamide, irreversibly committing NAM to methylation rather than NAD+ salvage synthesis. NNMT activity is elevated in obesity, type 2 diabetes, cancer, and inflammatory states. This upregulation creates a metabolic trap: high NNMT activity simultaneously depletes NAM (reducing NAD+ biosynthetic flux) and SAM (reducing capacity for all other cellular methylation reactions including DNA and histone methylation).
5-Amino-1MQ is a competitive inhibitor of NNMT's NAM binding site, with an IC₅₀ in the nanomolar range. By blocking NNMT, it diverts NAM back into the NAD+ salvage pathway (NAM → NMN → NAD+ via NAMPT), increasing cellular NAD+ availability. Simultaneously, SAM is preserved, restoring methylation capacity. This dual benefit — increased NAD+ and restored methylation — has implications for metabolic disease, epigenetic regulation, and cellular ageing research.
The most extensively published research on 5-Amino-1MQ and related NNMT inhibitors (including methylquinolinium derivatives developed at Vanderbilt University) has examined adipogenesis and fat mass. Key findings:
Because 5-Amino-1MQ increases NAM availability for NAD+ synthesis, it is studied as a complementary approach to direct NAD+ precursor supplementation. In research models where tissue NAD+ is depleted (ageing, diabetes, ischaemia), NNMT inhibition may amplify the effect of NMN or NR supplementation by reducing NAM excretion. Researchers studying NAD+ metabolism often combine NNMT inhibitors with NAD+ precursors to examine pathway flux dynamics.
NNMT overexpression is documented in multiple tumour types and has been associated with cancer aggressiveness, resistance to chemotherapy, and enhanced cancer stem cell properties. NNMT inhibition has been studied as a potential anti-tumour strategy, with in-vitro data showing reduced cancer cell proliferation and impaired migration in NNMT-overexpressing cancer cell lines.
The SAM-preserving effect of NNMT inhibition has implications for epigenetic research. SAM is the universal methyl donor for DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs). NNMT-mediated SAM depletion in obese adipose tissue has been linked to hypomethylation of metabolic gene promoters. 5-Amino-1MQ provides a tool to study this epigenetic axis in metabolic disease models.
